Clinical Trial Update: Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating ranibizumab to inhibit corneal neovascularization after corneal transplant surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Neovascularization

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: University of Miami | Conditions: Corneal Neovascularization | Phase 1 | Status: COMPLETED